
Join to view full profile
8301 Harcourt RdSte 200Indianapolis, IN 46260
Phone+1 317-415-6600
Fax+1 317-415-6649
Dr. Birhiray is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ruemu Birhiray is an oncologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Ascension St. Vincent Carmel Hospital, Witham Health Services, Ascension St. Vincent Indianapolis Hospital, Riverview Health, and Logansport Memorial Hospital. He received his medical degree from University of Benin Faculty of Medicine and has been in practice 31 years. He specializes in hematologic oncology and is experienced in squamous cell carcinoma of the esophagus, lung cancer, bone marrow transplantation, multiple myeloma, and spinal ependymoma.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 1998
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Columbus HospitalResidency, Internal Medicine, 1992 - 1995
University of Benin Faculty of MedicineClass of 1986
Certifications & Licensure
IN State Medical License 2000 - 2027
WI State Medical License 1998 - 2001
MD State Medical License 1995 - 1998
IL State Medical License 1994 - 1996
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Indianapolis Monthly Castle Connolly, 2011, 2013-2019
- CMS Meaningful Use Stage 2 Certification GeniusDoc, GeniusDoc, Inc., 2014-2017
- CMS Meaningful Use Stage 1 Certification GeniusDoc EHR, GeniusDoc, Inc., 2014-2017
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Dec 10
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Start of enrollment: 2018 Nov 28
Publications & Presentations
PubMed
- Long-Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations.Ruemu E Birhiray, Maya N Birhiray, Samuel L Ranger, Vincent L Flanders
Case Reports in Oncological Medicine. 2025-01-01 - 20 citationsSequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma.Joseph Lownik, Jonathan Boiarsky, Ruemu Birhiray, Akil Merchant, Monica Mead
Clinical Cancer Research. 2024-07-15 - 6 citations-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter
Future Oncology. 2024-01-01
Abstracts/Posters
- Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...Ruemu Ejedafeta Birhiray, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...Ruemu Ejedafeta Birhiray, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Indiana Black Expo to Present Award to Mathew Knowles for Health AdvocacyJuly 6th, 2026
“Substantial” Reduction in Risk for Progression or Death in RR/FL with Epcoritamab Plus R2December 8th, 2025
Newer TKIs Being Tested for Systemic MastocytosisJuly 15th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: